RRoche Read More Roche Holding (SWX:ROG) Valuation Check After Key FDA And Phase III Milestones2026-02-27 Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
GGlencore Read More Is It Too Late To Consider Glencore (LSE:GLEN) After A 71% One-Year Rally?2026-02-27 Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. If…
UUBS Read More Should UBS’s Upgrade and Deal Talks Prompt a Rethink of BlackRock’s (BLK) Evolving Profit Engine?2026-02-26 Over the past week, BlackRock has featured in multiple developments, including an analyst upgrade at UBS, insider share…
NNovartis Read More Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones2026-02-25 Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
CChubb Read More Facts to Know Before Betting on It2026-02-24 Chubb (CB) has recently been on Zacks.com’s list of the most searched stocks. Therefore, you might want to…
AABB Read More Is ABB (SWX:ABBN) Still Attractively Priced After Its Strong Multi Year Share Price Run2026-02-23 Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
AABB Read More Assessing ABB (SWX:ABBN) Valuation After Strong Recent Share Price Momentum2026-02-21 Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
UUBS Read More What Veracyte (VCYT)’s UBS Rating Reaffirmation and 2026 Outlook Means For Shareholders2026-02-19 UBS recently reaffirmed its Buy rating on Veracyte after the company’s fourth-quarter testing revenue came in ahead of…
RRoche Read More Looking at the Narrative for Roche After New Trial Results and Strategic Shifts2026-02-19 Roche Holding’s fair value estimate has edged up to about CHF 312 from roughly CHF 305, supported by…
RRoche Read More Assessing Valuation After Recent Quiet Uptrend in Share Price2026-02-18 If you have been watching Roche Holding (SWX:ROG), you might be wondering what to make of its recent…
RRoche Read More How the Narrative Around Roche Is Evolving Amid Analyst Updates and Clinical Shifts2026-02-17 Roche Holding’s fair value estimate has seen a modest increase, with the latest target rising from CHF 298.64…
RRoche Read More Is FDA’s Fast Subcutaneous Lunsumio VELO Approval Reshaping the Investment Case For Roche (SWX:ROG)?2026-02-17 In December 2025, Genentech, part of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a…